Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
- Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
- First clinical data supports imlifidase ability to substantially reduce antiAAV antibodies to allow administration of gene therapy.
Lund, Sweden, 30 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report for January-September 2025.
